{"article_link": "https://www.frontiersin.org/articles/10.3389/fcell.2021.649265/full", "data": [{"id": "data_1", "omics": "Transcriptomics", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163574", "format": "txt", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE163574"}, {"id": "data_2", "omics": "Proteomics", "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023344", "format": "raw", "source": "ProteomeXchange", "public_id": "PXD023344"}, {"id": "data_3", "omics": "Phosphoproteomics", "link": "https://www.ebi.ac.uk/pride/archive/projects/PXD023345", "format": "raw", "source": "ProteomeXchange", "public_id": "PXD023345"}, {"id": "data_4", "omics": "Transcriptomics", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62452", "format": "tsv", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE62452"}, {"id": "data_5", "omics": "Transcriptomics", "link": "https://dcc.icgc.org/projects/ICGC-AU", "format": "txt", "source": "International Cancer Genome Consortium (ICGC)", "public_id": "ICGC-AU"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://portal.gdc.cancer.gov/studies/TCGA-PAAD", "format": "tsv", "source": "The Cancer Genome Atlas (TCGA)", "public_id": "TCGA-PAAD"}], "analyses": [{"id": "analysis_1", "analysis_type": "RNA-seq transcriptomics profiling", "analysis_data": ["data_1"], "label": {"Treatment": ["anlotinib", "DMSO"]}}, {"id": "analysis_2", "analysis_type": "Differential gene expression analysis", "analysis_data": ["data_1"], "label": {"Fold change threshold": [">=2"], "FDR threshold": ["<0.05"]}}, {"id": "analysis_3", "analysis_type": "Canonical pathway analysis using IPA", "analysis_data": ["analysis_2"], "label": {"Pathway Category": ["Cell cycle", "Ribosome", "DNA Damage Response"]}}, {"id": "analysis_4", "analysis_type": "Differential proteomics analysis", "analysis_data": ["data_2"], "label": {"Fold change threshold": [">1.2"], "p-value threshold": ["<0.05"]}}, {"id": "analysis_5", "analysis_type": "Differential phosphoproteomics analysis", "analysis_data": ["data_3"], "label": {"Fold change threshold": [">1.2"], "p-value threshold": ["<0.05"]}}, {"id": "analysis_6", "analysis_type": "Integrative multi-omics analysis", "analysis_data": ["analysis_2", "analysis_4", "analysis_5"], "label": {"Regulatory Mechanism": ["Post-transcriptional regulation", "Ribosome", "Lysosome"]}}, {"id": "analysis_7", "analysis_type": "Prognostic gene signature development", "analysis_data": ["analysis_6"], "label": {"Risk Score Stratification": ["High", "Low"]}, "features": ["TOP2A", "CRABP2", "CDK1", "NUSAP1", "PERP"]}, {"id": "analysis_8", "analysis_type": "Multivariate Cox regression analysis", "analysis_data": ["analysis_7"], "label": {"Prognostic Factors": ["Risk Score", "N Stage"]}, "features": ["Independent prognostic factors", "Risk score", "N stage"]}, {"id": "analysis_9", "analysis_type": "Time-dependent ROC analysis", "analysis_data": ["analysis_7"], "label": {"Cohort": ["TCGA-PAAD", "GSE62452", "ICGC-AU"]}, "features": ["Best performance in GSE62452 cohort"]}], "results": [{"analysis_id": "analysis_1", "metric": "IC50", "value": "5.535 μM (PANC-1); 4.642 μM (AsPC-1)", "features": []}, {"analysis_id": "analysis_2", "metric": "Number of DEGs", "value": "992", "features": ["Unfolded protein response", "Cell cycle: G2/M DNA damage checkpoint regulation", "p53 signaling pathway"]}, {"analysis_id": "analysis_3", "metric": "Enriched pathways", "value": "24 cancer-related canonical pathways", "features": []}, {"analysis_id": "analysis_4", "metric": "Number of differentially expressed proteins", "value": "1046", "features": ["Ribosome", "Lysosome"]}, {"analysis_id": "analysis_5", "metric": "Number of differentially phosphorylated peptides", "value": "4323", "features": ["Cell cycle", "RNA transport", "Spliceosome"]}, {"analysis_id": "analysis_6", "metric": "Shared mechanisms", "value": "Post-transcriptional regulation of ribosome and lysosome", "features": ["Ribosome biogenesis", "Lysosomal function"]}, {"analysis_id": "analysis_7", "metric": "Stratification accuracy", "value": "57% of patients classified into high-risk subgroup", "features": []}, {"analysis_id": "analysis_8", "metric": "Hazard Ratio (HR)", "value": "2.318 (risk score); 1.831 (N stage)", "features": ["Independent prognostic factors"]}, {"analysis_id": "analysis_9", "metric": "Time-dependent AUC", "value": {"TCGA-PAAD": {"3 years": 0.7, "5 years": 0.72}, "GSE62452": {"3 years": 0.87, "5 years": 0.85}, "ICGC-AU": {"3 years": 0.65, "5 years": 0.75}}, "features": ["Best performance in GSE62452 cohort"]}]}